What is ADXN's current stock price?

ADXN (Addex Therapeutics Ltd) is currently trading at $6.83 with a market cap of $4.9M.

What sector is Addex Therapeutics Ltd in?

Addex Therapeutics Ltd (ADXN) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ADXN a good stock to buy?

Analysts have a Buy consensus on ADXN with a price target of $30.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ADXN Addex Therapeutics Ltd

Healthcare

$6.83-2.29%ClosedMarket Cap: $4.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.41

P/S

46.87

EV/EBITDA

-0.96

DCF Value

$1.47

FCF Yield

-30.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

-4.8%

Operating Margin

-1839.8%

Net Margin

-4398.5%

ROE

-102.6%

ROA

-105.8%

ROIC

-54.5%

Financials

View All

Period	Revenue	Net Income	EPS
Q4 null	$248.00	$-1.8M	$—
FY null	$30.0K	$-6.4M	$—
Q3 null	$29.7K	$-1.6M	$—
Q2 null	$36.4K	$-1.8M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$30.00

Target (Median)

$30.00

Target Range

$30.00 - $30.00

1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Teyssedou Lenaic Nathanaelofficer: PRINCIPAL ACCOUNTING OFFICER

SellWed Mar 25

Teyssedou Lenaic Nathanaelofficer: PRINCIPAL ACCOUNTING OFFICER

SellWed Mar 25

Teyssedou Lenaic Nathanaelofficer: PRINCIPAL ACCOUNTING OFFICER

SellWed Mar 25

Mills Rogerdirector, officer: CHIEF MEDICAL OFFICER

SellWed Mar 25

Mills Rogerdirector, officer: CHIEF MEDICAL OFFICER

SellWed Mar 25

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.98

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Peers

IBO

NBY